Skip to main content

Study of TJ011133 Subjects With Relapsed / Refractory Advanced Solid Tumors and Lymphoma

Trial Status: Active

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

Inclusion Criteria

  • Part 1: Subjects with advanced relapsed/refractory solid tumors and lymphoma
  • Part 2 with Rituximab: Subjects with DLBCL or Indolent B-cell Lymphoma, with at least one measurable lesion by Lugano and available fresh metastatic biopsy sample prior to study entry.
  • Part 2 with Pembrolizumab: Subject with locally advanced non-small-cell lung carcinoma (NSCLC) with disease progression, Urothelial (bladder) cancer that is not eligible for cisplatin-containing chemotherapy or has progressed following cisplatin-containing chemotherapy, or immune-oncology treatment naive Epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with at least one measurable lesion defined by RECIST 1.1, and available fresh metastatic biopsy prior to study entry.
  • All Parts: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 and adequate bone marrow, renal, and liver functions.

Exclusion Criteria

  • Subjects with known symptomatic central nervous system tumors or known central nervous system metastases or leptomeningeal disease requiring steroids. Subjects who document stable and central nervous system metastases and are off steroids for more than 4 weeks may be enrolled in the study
  • Subjects with Burkitt's lymphoma, lymphoblastic lymphoma, Richter's transformation, primary effusion lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Subjects with mantle cell lymphoma
  • Impaired cardiac function or clinically significant cardiac diseases
  • Prior treatment with CD47 or SIRPα inhibitors
  • Prior autologous stem cell transplant ≤3 months prior to starting study
  • Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning
  • Prior chimeric antigen receptor or chimeric antigen receptor T-cell therapy
  • History of autoimmune anemia or autoimmune thrombocytopenia
  • Positive Direct Antiglobulin Test
  • Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD


University of Alabama at Birmingham Cancer Center
Status: ACTIVE
Contact: Lakshminarayanan Nandagopal
Phone: 205-975-5715


Mayo Clinic in Arizona
Status: ACTIVE


City of Hope Comprehensive Cancer Center
Status: ACTIVE


Mayo Clinic in Florida
Status: ACTIVE


Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE


Mayo Clinic in Rochester
Status: ACTIVE

New York

New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: ACTIVE


Vanderbilt University / Ingram Cancer Center
Status: ACTIVE


Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety,

tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD),

pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an

anti-CD47 antibody, in subjects with advanced relapsed or refractory solid tumors and

lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose

escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with

pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
I-Mab Biopharma Co. Ltd.

  • Primary ID TJ011133EDI101
  • Secondary IDs NCI-2019-03119, KN-A21, KEYNOTE KN-A21
  • ID NCT03934814